Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib

Lung Cancer

Volumn 81, Issue 1, 2013, Pages 142-143

  Bos, M ^a   Gardizi, M ^a   Schildhaus, H U ^a   Heukamp, L C ^a   Geist, T ^b   Kaminsky, B ^c   Zander, T ^a   Nogova, L ^a   Scheffler, M ^a   Dietlein, M ^a   Kobe, C ^a   Holstein, A ^a   Maintz, D ^a   Buttner R ^a   Wolf, J ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Florence Nightingale Hospital   (Germany)

^c Bethanien Hospital   (Germany)

Author keywords

Crizotinib; Lung cancer; NSCLC; Personalized medicine; ROS1

Indexed keywords

ALK PROTEIN; B RAF KINASE; CARBOPLATIN; CETUXIMAB; CRIZOTINIB; DDR2 PROTEIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN RET; RAS PROTEIN; ROS1 PROTEIN; SUNITINIB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CHROMOSOME ABERRATION; DYSPNEA; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; METABOLIC BALANCE; MOLECULAR DIAGNOSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCREENING TEST; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE REARRANGEMENT; GENES, RETINOBLASTOMA; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES; TREATMENT OUTCOME;

EID: 84878975043     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.02.018     Document Type: Article

References (3)

1. Acquaviva J., Wong R., Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta 2009, 1795(January 1):37-52.
2. Bergethon K., Shaw A.T., Ou S-HI, Katayama R., Lovly C.M., McDonald N.T., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012 Mar 10, 30(8):863-870.
3. Ou S.I., Camidge D.R., Engelman J., Clark J., Tye L., Wilner K., et al. Clinical activity of crizotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. Ann Oncol 2012, 23(September (Suppl 9)):ix389-ix399.